Karl‐Erik Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Karl‐Erik Andersson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Annette Schröder
Department of Clinical and Experimental Pharmacology, Lund University Hospital, Sweden
1 shared publicationB. Larsson
Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
1 shared publicationB. Sandberg
Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden
1 shared publication- Christopher Reginald Chapple
Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
1 shared publication Claus G. Roehrborn
UT Southwestern Medical Center at Dallas, Dallas, Texas
1 shared publicationElmar Friderichs
22Grünenthal GmbH, Aachen, Germany
1 shared publication
Latest Publications
- 31 January 2011
- Published by Wiley in Neurourology and Urodynamics
- Vol. 30 (3) , 292-301
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
Background: The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical studies of tadalafil and other PDE5 inhibitors have reported significant symptom reduction but limited urinary flow rate improvement. This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.Methods: Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files. Articles were selected for review based on describing in vitro, preclinical, or clinical studies of pathological processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.Results: Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia. Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.Conclusions: The pathophysiology of male LUTS is complex and not completely understood. LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap. While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS. Neurourol. Urodynam. 30:292–301, 2011.
- 31 January 2011
- Published by Wiley in Neurourology and Urodynamics
- Vol. 30 (3) , 292-301
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
Background: The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical studies of tadalafil and other PDE5 inhibitors have reported significant symptom reduction but limited urinary flow rate improvement. This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.Methods: Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files. Articles were selected for review based on describing in vitro, preclinical, or clinical studies of pathological processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.Results: Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia. Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.Conclusions: The pathophysiology of male LUTS is complex and not completely understood. LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap. While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS. Neurourol. Urodynam. 30:292–301, 2011.
- Open Access
- 2 August 2006
- Published by Wiley in BJU International
- Vol. 98 (3) , 637-642
Effects of a vitamin D 3 analogue in a rat model of bladder outlet obstruction
OBJECTIVES: To explore the effect of the vitamin D 3 analogue, BXL‐628, on some of the consequences of bladder outlet obstruction (BOO), e.g. hypertrophy and loss of contractile function, as vitamin D 3 and BXL‐628 inhibit prostate and bladder cell growth in vitro , and there are receptors for vitamin D in rat and human bladder. MATERIAL AND METHODS: In female rats, BOO was produced by a standardized method; one group received daily BXL‐628 (150 µg/kg per day) and the remaining rats received vehicle. Sham‐operated rats received BXL‐628 or vehicle. After 2 weeks, the conscious rats were assessed by cystometry. Plasma calcium levels were determined and in vitro contractility assessed at the end of the experiments. RESULTS: There was a significant increase in bladder weight, micturition interval and volume, and in bladder capacity in both the obstructed groups compared to sham controls, but no difference between the obstructed groups. On plotting the micturition pressure against bladder weight within the obstructed groups, there was a clear correlation in the vehicle‐treated group, indicating a decrease in contractile function with increasing bladder weight. There was no such correlation in the treatment group. In vitro , there was a strong correlation of increasing bladder weights vs decrease in response to KCl and electrical‐field stimulation in strips from obstructed vehicle‐treated rats, but no correlation in those from drug‐treated rats. Treatment increased the plasma calcium level by 12%. CONCLUSIONS: The vitamin D 3 analogue used did not prevent bladder hypertrophy, but appeared to reduce some of the negative functional changes of the bladder smooth muscle, which occurs with BOO‐induced increases in bladder weight.
- 2 August 2006
- Published by Wiley in BJU International
- Vol. 98 (3) , 637-642
Open AccessEffects of a vitamin D 3 analogue in a rat model of bladder outlet obstruction
OBJECTIVES: To explore the effect of the vitamin D 3 analogue, BXL‐628, on some of the consequences of bladder outlet obstruction (BOO), e.g. hypertrophy and loss of contractile function, as vitamin D 3 and BXL‐628 inhibit prostate and bladder cell growth in vitro , and there are receptors for vitamin D in rat and human bladder. MATERIAL AND METHODS: In female rats, BOO was produced by a standardized method; one group received daily BXL‐628 (150 µg/kg per day) and the remaining rats received vehicle. Sham‐operated rats received BXL‐628 or vehicle. After 2 weeks, the conscious rats were assessed by cystometry. Plasma calcium levels were determined and in vitro contractility assessed at the end of the experiments. RESULTS: There was a significant increase in bladder weight, micturition interval and volume, and in bladder capacity in both the obstructed groups compared to sham controls, but no difference between the obstructed groups. On plotting the micturition pressure against bladder weight within the obstructed groups, there was a clear correlation in the vehicle‐treated group, indicating a decrease in contractile function with increasing bladder weight. There was no such correlation in the treatment group. In vitro , there was a strong correlation of increasing bladder weights vs decrease in response to KCl and electrical‐field stimulation in strips from obstructed vehicle‐treated rats, but no correlation in those from drug‐treated rats. Treatment increased the plasma calcium level by 12%. CONCLUSIONS: The vitamin D 3 analogue used did not prevent bladder hypertrophy, but appeared to reduce some of the negative functional changes of the bladder smooth muscle, which occurs with BOO‐induced increases in bladder weight.
- 1 June 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (4) , 741-748
Actions of tramadol on micturition in awake, freely moving rats
(±)‐Tramadol, a widely used analgesic, is a racemate stimulating opioid receptors and inhibiting reuptake of noradrenaline and serotonin, that is, pharmacological principles previously shown to influence rat micturition. We studied both (±)‐tramadol and its enantiomers in conscious Sprague–Dawley rats undergoing continuous cystometry. The effects of these agents were compared to those of morphine (μ‐opioid receptor agonist) and tested after pretreatment with naloxone (μ‐opioid receptor antagonist). Cystometries were evaluated before and after intravenous (i.v.), intraperitoneal (i.p.) and intrathecal (i.t.) drug administrations. The most conspicuous effects of i.v. (±)‐tramadol (0.1–10 mg kg−1) was an increase in threshold pressure and an increase in micturition volume. These effects were mimicked by (+)‐tramadol (0.1–5 mg kg−1 i.v.), whereas (−)‐tramadol (5 mg kg−1 i.v.) did not influence threshold pressure and micturition volume. The effects of (±)‐tramadol 5 mg kg−1 on micturition volume were blocked by pretreatment with naloxone 0.3 mg kg−1. Morphine (0.3–10 mg kg−1 i.p.) increased threshold pressure but did not significantly increase micturition volume in doses not resulting in overflow incontinence. (±)‐Tramadol 10 mg kg−1 increased urine production, an effect blocked by desmopressin 25 ng kg−1. (±)‐Tramadol effectively inhibits micturition in conscious rats by stimulating μ‐opioid receptors. A synergy between opioid receptor stimulation and monoamine reuptake inhibition may contribute to the micturition effects. British Journal of Pharmacology (2003) 139, 741–748. doi:10.1038/sj.bjp.0705297
- 1 June 2003
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (4) , 741-748
Actions of tramadol on micturition in awake, freely moving rats
(±)‐Tramadol, a widely used analgesic, is a racemate stimulating opioid receptors and inhibiting reuptake of noradrenaline and serotonin, that is, pharmacological principles previously shown to influence rat micturition. We studied both (±)‐tramadol and its enantiomers in conscious Sprague–Dawley rats undergoing continuous cystometry. The effects of these agents were compared to those of morphine (μ‐opioid receptor agonist) and tested after pretreatment with naloxone (μ‐opioid receptor antagonist). Cystometries were evaluated before and after intravenous (i.v.), intraperitoneal (i.p.) and intrathecal (i.t.) drug administrations. The most conspicuous effects of i.v. (±)‐tramadol (0.1–10 mg kg−1) was an increase in threshold pressure and an increase in micturition volume. These effects were mimicked by (+)‐tramadol (0.1–5 mg kg−1 i.v.), whereas (−)‐tramadol (5 mg kg−1 i.v.) did not influence threshold pressure and micturition volume. The effects of (±)‐tramadol 5 mg kg−1 on micturition volume were blocked by pretreatment with naloxone 0.3 mg kg−1. Morphine (0.3–10 mg kg−1 i.p.) increased threshold pressure but did not significantly increase micturition volume in doses not resulting in overflow incontinence. (±)‐Tramadol 10 mg kg−1 increased urine production, an effect blocked by desmopressin 25 ng kg−1. (±)‐Tramadol effectively inhibits micturition in conscious rats by stimulating μ‐opioid receptors. A synergy between opioid receptor stimulation and monoamine reuptake inhibition may contribute to the micturition effects. British Journal of Pharmacology (2003) 139, 741–748. doi:10.1038/sj.bjp.0705297
- 6 December 2001
- Published by Wiley in Neurourology and Urodynamics
- Vol. 21 (1) , 92-98
Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.
- 6 December 2001
- Published by Wiley in Neurourology and Urodynamics
- Vol. 21 (1) , 92-98
Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.
- Open Access
- 24 December 1999
- Published by Wiley in BJU International
- Vol. 84 (9) , 923-947
The pharmacological treatment of urinary incontinence
- 24 December 1999
- Published by Wiley in BJU International
- Vol. 84 (9) , 923-947
Open AccessThe pharmacological treatment of urinary incontinence